[64Cu]Cu-DOTATATE PET was able to detect a difference in uptake in the treated group, even though the included participants were not selected based on an increased cardiovascular risk beyond that of type 2 diabetes itself, as was the case in many of the larger trials investigating the effects of GLP1-RA’s on cardiovascular outcomes (7, 9, 10, 25). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.